Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

90.31USD
11:15am EDT
Change (% chg)

$1.04 (+1.17%)
Prev Close
$89.27
Open
$89.99
Day's High
$90.80
Day's Low
$89.46
Volume
1,272,580
Avg. Vol
6,352,741
52-wk High
$147.17
52-wk Low
$74.13

Chart for

About

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)

Overall

Beta: 1.32
Market Cap(Mil.): $65,208.79
Shares Outstanding(Mil.): 703.36
Dividend: --
Yield (%): --

Financials

  CELG.O Industry Sector
P/E (TTM): 16.92 28.12 30.20
EPS (TTM): 5.28 -- --
ROI: 14.52 13.07 12.77
ROE: 68.50 15.04 14.92

Celgene profit tops expectations, will limit future price hikes

Celgene Corp on Thursday posted better-than-expected second quarter profit, powered by a 21 percent jump in sales of its blockbuster cancer drug Revlimid, and the U.S. biotech promised to limit future price increases on its medicines. The company joined several rivals in bowing to pressure from the administration of U.S. President Donald Trump to rein in rising costs of prescription drugs to U.S. patients.

Jul 26 2018

UPDATE 2-Celgene profit tops expectations, will limit future price hikes

* Revlimid sales beat Wall Street estimates (Adds company, analyst comment, background, share movement)

Jul 26 2018

Celgene quarterly profit drops 5 pct

July 26 U.S. drugmaker Celgene Corp reported a 5 percent drop in quarterly profit on Thursday, hurt by higher expenses.

Jul 26 2018

BRIEF-Celgene Corp Says Phase III Impassion130 Study Met Co-Primary Endpoint Of Progression-Free Survival

* ANTI-PD-L1 IMMUNOTHERAPY PLUS ABRAXANE® SIGNIFICANTLY REDUCED THE RISK OF DISEASE WORSENING OR DEATH IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER IN PHASE III IMPASSION130 STUDY

Jul 10 2018

BRIEF-Evotec And Celgene Enter Into Strategic Oncology Partnership

* DGAP-ADHOC: EVOTEC AND CELGENE ENTER INTO STRATEGIC ONCOLOGY PARTNERSHIP

May 21 2018

Celgene profit tops estimates; clarifies path for key MS drug

Celgene Corp reported much-needed, stronger-than-expected first quarter results as profit and sales of several drugs exceeded Wall Street forecasts, and the U.S. biotechnology company said it would re-apply for approval of an important multiple sclerosis treatment in early 2019.

May 04 2018

UPDATE 3-Celgene profit tops estimates; clarifies path for key MS drug

May 4 Celgene Corp reported much-needed, stronger-than-expected first quarter results as profit and sales of several drugs exceeded Wall Street forecasts, and the U.S. biotechnology company said it would re-apply for approval of an important multiple sclerosis treatment in early 2019.

May 04 2018

CORRECTED-UPDATE 2-Celgene tops estimates on higher demand for cancer drug Revlimid

* To resubmit ozanimod marketing application earlier than expected

May 04 2018

BRIEF-Celgene Reports Q1 Adjusted Earnings Per Share Of $2.05

* CELGENE REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS

May 04 2018

Celgene's quarterly profit dips 9 percent

May 4 Celgene Corp's quarterly profit fell about 9 percent despite the U.S. biotech reporting higher revenue, as its expenses surged.

May 04 2018

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥4,613 +73.00
Eisai Co., Ltd (4523.T) ¥9,735 -19.00
Johnson & Johnson (JNJ.N) $131.67 +1.24
Novartis AG (NOVN.S) CHF81.64 +0.78
Pfizer Inc. (PFE.N) $41.22 +0.06
Roche Holding Ltd. (ROG.S) CHF239.60 +2.35
Roche Holding Ltd. (RO.S) CHF243.40 +2.80
Merck & Co., Inc. (MRK.N) $68.27 +0.90
Sanofi SA (SASY.PA) €72.52 +0.36
AstraZeneca plc (AZN.L) 5,928.00 -14.00

Earnings vs. Estimates